Your Streamlined Solution
for Medicaid Value-Based
Purchasing Agreements
for Medicaid Value-Based
Purchasing Agreements
Your Medicaid program does not need to face these challenges alone.
From advanced cell and gene therapies to rapidly expanding GLP-1s and oncology treatments, next-generation drugs are adding unprecedented cost pressure. At the same time, evolving policy expectations and data requirements are increasing administrative strain and contract complexity.
Lyfegen and CMA simplify these challenges, offering State Medicaid programs a streamlined, data-driven solution to manage cost pressure and complexity through smarter Value-Based Purchasing Agreements (VBPAs).
Get Better Purchasing Agreements and Extract More Value
Together, Lyfegen and CMA help states streamline Value-Based Purchasing Agreements, combining leading technology, proven contracting capabilities, and data-driven insights to simplify how states manage innovative drug pricing models. We enable Medicaid programs to move from labor intensive and cumbersome processes to automated, transparent, and efficient contracting operations.
Demonstrated ability to address the nuanced requirements of VBPAs.
Highly specialized expertise, focus and capacity.
Proven set of unique technology accelerators
Our Approach
For value-based agreements and emerging pricing models.
Contracts tailored to therapeutic and budget priorities.
Agreements with automation, accuracy, and transparency.
CEO of Helgerson Solutions
Group Former New York State Medicaid Director
Lyfegen Advisory Board
